SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Novocure CEO Says Daraxonrasib Slowed Optune Pax Adoption

CEO Frank Leonard said the drug’s launch slowed adoption of Novocure’s Optune Pax device. Wedbush attributed the change more to disruption at medical practices than direct displacement. Novocure shares were down about 4% at the time of writing.

NVCR
SquawkNews Desk

Related stories

Australian Energy Stocks Reach One-Week High as Oil Rises Australian energy stocks reached a one-week high as supply concerns lifted oil prices. M impact | EQUITY | Oct 30, 2026, 04:03 AM UTC Nasdaq 100 futures fall 2%; S&P 500 futures down almost 1% M impact | EQUITY | Oct 30, 2026, 04:03 AM UTC U.S. Stock Futures Fall as Intel and Amazon Earnings Weigh At 11:44 p.m. EDT, Dow futures fell 0.17%, S&P 500 futures fell 0.95% and Nasdaq-100 futures fell more than 2% after disappointing earnings from Intel and Amazon. M impact | EQUITY | Oct 30, 2026, 04:03 AM UTC Janome to Buy Back Up to 5.98% of Shares L impact | EQUITY | Oct 30, 2026, 04:02 AM UTC Asian session market picture: S&P 500 -0.94%, Nasdaq 100 -2.06%; USD/JPY -0.15%, WTI +1.18%, 1810 leads volume Asian session market picture. US index futures: S and P futures is down 0.94 percent, Nasdaq futures is down 2.06 percent, Dow futures is down 0.19 percent and Russell futures is d M impact | EQUITY | Oct 30, 2026, 04:00 AM UTC Hengsheng Real Estate Delisted on Nov. 3 Hengsheng Real Estate’s listing status was formally revoked on Nov. 3. L impact | EQUITY | Oct 30, 2026, 03:59 AM UTC